|
Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - inVentiv Health (Inst); Merck (Inst); Pfizer/EMD Serono (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pfizer; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Novartis |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Serono; MSD; Ono Pharmaceutical |
Consulting or Advisory Role - Amgen; Aspyrian Therapeutics; Bristol-Myers Squibb; Celgene; MSD; Ono Pharmaceutical; Pfizer |
Research Funding - Aspyrian Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst) |